Ceapro appoints Ulrich Kosciessa to board
This article was originally published in Scrip
Ceapro, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, has appointed international pharmaceutical industry expert Dr Ulrich Kosciessa to its board of directors. Dr Kosciessa has over two decades of research, business development and marketing leadership experience. He is a member of the executive management board of Medac, a global pharmaceutical company with operations in 70 countries, managing director of Medac, and chair of the board of Medac Pharma, a US-based subsidiary of Medac focused on specialty pharmaceuticals for autoimmune diseases and cancer.